Research programme: casein kinase I alpha stimulants - StemSynergy Therapeutics

Drug Profile

Research programme: casein kinase I alpha stimulants - StemSynergy Therapeutics

Alternative Names: SSTC-104; SSTC3

Latest Information Update: 21 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator StemSynergy Therapeutics
  • Class Small molecules
  • Mechanism of Action Casein kinase Ialpha stimulants; Wnt signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Colorectal cancer; Synovial sarcoma

Most Recent Events

  • 17 Jul 2017 Preclinical trials in Colorectal cancer in USA, before July 2017
  • 14 Jul 2017 StemSynergy Therapeutics plans a phase I trial for Colorectal cancer
  • 08 Aug 2013 Preclinical trials in Synovial sarcoma in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top